Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 mill...

Full description

Saved in:
Bibliographic Details
Published in:Infectious diseases and therapy 2015-06, Vol.4 (2), p.145-157
Main Authors: Ustianowski, Andrew, Arends, Joop E.
Format: Article
Language:English
Subjects:
Antiretroviral drugs
HIV
Human immunodeficiency virus
Infectious Diseases
Internal Medicine
Medicine
Medicine & Public Health
Pharmacology
Review
Side effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.
ISSN:2193-8229
2193-6382
DOI:10.1007/s40121-015-0070-1